Diabetes and CYP2C19 polymorphism synergistically impair the antiplatelet activity of clopidogrel compared with ticagrelor in percutaneous coronary intervention-treated acute coronary syndrome patients

Citation:
Mohareb, M. W., M. AbdelGhany, H. F. Zaki, and H. S. El-Abhar, "Diabetes and CYP2C19 polymorphism synergistically impair the antiplatelet activity of clopidogrel compared with ticagrelor in percutaneous coronary intervention-treated acute coronary syndrome patients", Journal of Cardiovascular Pharmacology, vol. 76, pp. 478-488, 2020.